MLS101 Study in PMDD

Clinical trial registration, sponsored by MycoMedica Life Sciences PBC, registered 14 Sep 2026.

Phase 1 · not yet recruiting · n = 32

Tags: Registry, Psilocybin.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 11: 20 new trials registered

New registrations include psilocybin for methamphetamine use disorder, borderline personality disorder, nicotine craving and premenstrual dysphoric disorder, and a National Institute on Aging trial pairing psilocybin with cognitive training. Results were posted for psilocybin in depression and anxiety in Parkinson's disease.

How much weight it carries: Registrations show what is being attempted, not what was found. (Registry, Plans, not results)

Weekly Science Digest, 12 Sep 2026 to 18 Sep 2026, finding 6: In the clinic

Newly registered first-in-indication safety study of psilocybin for premenstrual dysphoric disorder, run by MycoMedica

How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)

Read the original

—
Node—
Statuslive
Throughput—